Literature DB >> 11286469

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors.

W Jacot1, X Quantin, J M Boher, F Andre, L Moreau, M Gainet, A Depierre, E Quoix, T L Chevalier, J L Pujol.   

Abstract

A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-therapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The accrual period was January 1991 to December 1998. Prognosis was analysed using both univariate and multivariate (Cox model) statistics. The median survival of the whole population was 28 weeks. Univariate analysis (log-rank), showed that patients affected by one of the following characteristics proved to have a shorter survival in comparison with the opposite status of each variable: male gender, age over 63 years, poor performance status, neurological symptoms, serum neuron-specific enolase (NSE) level higher than 12.5 ng ml(-1), high serum alkaline phosphatase level, high serum LDH level and serum sodium level below 132 mmol l(-1). In the Cox's model, the following variables were independent determinants of a poor outcome: male gender: hazard ratio (95% confidence interval): 2.29 (1.26-4.16), poor performance status: 1.73 (1.15-2.62), age: 1.02 (1.003-1.043), a high serum NSE level: 1.72 (1.11-2.68), neurological symptoms: 1.63 (1.05-2.54), and a low serum sodium level: 2.99 (1.17-7.62). Apart from 4 prognostic factors shared in common with other stage IV NSCLC patients, whatever the metastatic site (namely sex, age, gender, performance status and serum sodium level) this study discloses 2 determinants specifically resulting from brain metastasis: i.e. the presence of neurological symptoms and a high serum NSE level. The latter factor could be in relationship with the extent of normal brain tissue damage caused by the tumour as has been demonstrated after strokes. Additionally, the observation of a high NSE level as a prognostic determinant in NSCLC might reflect tumour heterogeneity and understimated neuroendocrine differentiation. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Year:  2001        PMID: 11286469      PMCID: PMC2363840          DOI: 10.1054/bjoc.2000.1706

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  49 in total

Review 1.  Pathology of carcinoma of the lung. Changing patterns.

Authors:  R Yesner; D Carter
Journal:  Clin Chest Med       Date:  1982-05       Impact factor: 2.878

2.  Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.

Authors:  J B Sørensen; H H Hansen; M Hansen; P Dombernowsky
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

3.  Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer.

Authors:  L G Jørgensen; H H Hansen; E H Cooper
Journal:  Eur J Cancer Clin Oncol       Date:  1989-01

4.  Regression models for prognostic prediction: advantages, problems, and suggested solutions.

Authors:  F E Harrell; K L Lee; D B Matchar; T A Reichert
Journal:  Cancer Treat Rep       Date:  1985-10

Review 5.  Chemotherapy for non-small cell lung cancer: have we reached a new plateau?

Authors:  F A Shepherd
Journal:  Semin Oncol       Date:  1999-02       Impact factor: 4.929

Review 6.  Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression.

Authors:  G L Nicolson
Journal:  Cancer Res       Date:  1987-03-15       Impact factor: 12.701

7.  Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction.

Authors:  R T Cunningham; I S Young; J Winder; M J O'Kane; S McKinstry; C F Johnston; O M Dolan; S A Hawkins; K D Buchanan
Journal:  Eur J Clin Invest       Date:  1991-10       Impact factor: 4.686

Review 8.  Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms.

Authors:  V E Gould; R I Linnoila; V A Memoli; W H Warren
Journal:  Lab Invest       Date:  1983-11       Impact factor: 5.662

9.  Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916.

Authors:  M Diener-West; T W Dobbins; T L Phillips; D F Nelson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

10.  A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916).

Authors:  L T Komarnicky; T L Phillips; K Martz; S Asbell; S Isaacson; R Urtasun
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-01       Impact factor: 7.038

View more
  23 in total

1.  Rapidly progressive dementia: an unusual cause.

Authors:  Aastha Takkar; Veenu Singla; Manish Modi; Vivek Gupta; Manoj K Goyal; Vivek Lal
Journal:  Neuroradiol J       Date:  2017-06-20

2.  Specific organ metastases and survival in metastatic non-small-cell lung cancer.

Authors:  Tomohiro Tamura; Koichi Kurishima; Kensuke Nakazawa; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2014-09-04

Review 3.  Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Debra Lynch Kelly; David Buchbinder; Rafael F Duarte; Jeffrey J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary E Flowers; Bipin Savani; Bronwen E Shaw
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-20       Impact factor: 5.742

4.  Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research.

Authors:  Carsten Nieder; Astrid Dalhaug; Ellinor Haukland; Bård Mannsåker; Adam Pawinski
Journal:  Tumour Biol       Date:  2015-03-24

5.  Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study.

Authors:  Mustafa S Ascha; Quinn T Ostrom; James Wright; Priya Kumthekar; Jeremy S Bordeaux; Andrew E Sloan; Fredrick R Schumacher; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05       Impact factor: 4.254

6.  Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.

Authors:  B Gagnon; M Abrahamowicz; Y Xiao; M-E Beauchamp; N MacDonald; G Kasymjanova; H Kreisman; D Small
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

7.  NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus.

Authors:  Hongjiang Yan; Renben Wang; Shumei Jiang; Kunli Zhu; Rui Feng; Xiaoqing Xu; Xiangjiao Meng
Journal:  Med Oncol       Date:  2013-12-05       Impact factor: 3.064

Review 8.  Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT.

Authors:  David Buchbinder; Debra Lynch Kelly; Rafael F Duarte; Jeffery J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne B Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary D E Flowers; Bipin Savani; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-01-17       Impact factor: 5.483

9.  Risk Factors, Prognosis, and a New Nomogram for Predicting Cancer-Specific Survival Among Lung Cancer Patients with Brain Metastasis: A Retrospective Study Based on SEER.

Authors:  Gui Hong Zhang; Yue Jiao Liu; Ming De Ji
Journal:  Lung       Date:  2022-01-24       Impact factor: 2.584

Review 10.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.